Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05454787

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)

Conditions: Life Threatening Bleeding, Factor Xa Inhibitor

Sex: All

Healthy volunteers: No

Enrollment: 300

Sponsor: AstraZeneca

Location: Research Site Aichi

Summary

This survey will be conducted to investigate the status of occurrence of the safety specifications set for "Safety specification" in patients who received Ondexxya Intravenous Injection 200 mg. In addition, this survey will be implemented to understand the followings by collecting safety and effectiveness information under actual use conditions.

Eligibility Criteria

Inclusion Criteria: * All patients treated with this drug to neutralize the anticoagulant effect of a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) at onset of a life-threatening bleeding episode or a unarrestable bleeding episode. Exclusion Criteria: * N/A

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05454787). StuddyBuddy aggregates publicly available trial information.